VCYT (Veracyte) רווח נקי למניה (EPS TTM)

Under the leadership of Mark Staple, Veracyte, Inc. (VCYT) is implementing high-precision genomic tests, earning the absolute trust of oncologists by minimizing unnecessary surgeries. The rolling net income per share trend captures this success, where the value 1.54 records the final metric. Business growth is supported by stringent patent protections and insurance company recognition, creating an insurmountable barrier for new entrants.

Biomaterial logistics and regulatory constraints in genomic diagnostics directly impact the operational efficiency of Veracyte, Inc. (VCYT), which is reflected in the rolling year net income per share trend. This indicator measures the final earnings attributable to a single share, allowing investors to assess the business's actual ability to generate profit regardless of the total capital volume.